Asahi Kasei Therapeutics Corp - Strategic SWOT Analysis Review

Asahi Kasei Therapeutics Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Report Scope

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - The analyst’s summarization of the company’s business strategy.
• SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Asahi Kasei Therapeutics Corp (Asahi Kasei Therapeutics), a subsidiary of Asahi Kasei Corp, manufactures and markets diagnostic reagents, prescription drugs, and enzymes for diagnostic reagents. Its prescription drugs are used in the treatment of osteoporosis pain, bone loss, dysuria accompanying benign prostatic hyperplasia, disseminated intravascular coagulation, proteinuria in nephrotic syndrome, nocturia and lupus nephritis, among others. Asahi Kasei Therapeutics offers assay kits for glycemic control and to detect prediabetes. The company’s pipeline products are intended for the treatment of chemotherapy-induced peripheral neuropathy, osteoporosis with high risk of fracture, Lupus nephritis and nephrotic syndrome, and severe sepsis with coagulopathy, among others. The company has facilities in Shizuoka, and Nagoya, Japan. Geographically, the company has business operations in the US, China and Japan. Asahi Kasei Therapeutics is headquartered in Tokyo, Japan.

Asahi Kasei Therapeutics Corp Key Recent Developments

• Feb 27, 2026: Asahi Kasei to acquire Aicuris Anti-infective Cures for $920.7m
• Feb 25, 2026: Asahi Kasei Pharma Secures Exclusive Global License From Alchemedicine for Novel Lead Compounds
• Jan 20, 2026: Aetai's Eternal Memorial Hall Built by Asahi Kasei Homes Completed
• Dec 22, 2025: Asahi Kasei Pharma to Move Global R&D Hub to Shonan iPark

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.